RESUMO
BACKGROUND: Female sexual dysfunction (FSD), including vaginal laxity (VL), can lead to a decrease in quality of life and affect partner relationships. AIM: We aimed to investigate the associated factors of VL and FSD and their relationship with other pelvic floor disorders in a female population. METHODS: This cross-sectional study was conducted at Chelsea and Westminster Hospital from July to December 2022. All women referred to clinical care at the urogynecology clinic were included. Participants were assessed according to sociodemographic and clinical aspects, the Pelvic Organ Prolapse Quantification system, sexual function, VL, sexual attitudes, sexual distress, sexual quality of life, vaginal symptoms, and pelvic floor disorders. Unadjusted and adjusted associated factors of VL and FSD were analyzed. OUTCOMES: The primary outcome was the identification of the associated factors of VL and FSD in a female population, and secondary outcomes included the association between VL and pelvic organ prolapse (POP) with the questionnaire scores. RESULTS: Among participants (N = 300), vaginal delivery, multiparity, perineal laceration, menopause, and gel hormone were significantly more frequent in those reporting VL (all P < .05). When compared with nulliparity, primiparity and multiparity increased the odds of VL by approximately 4 and 12 times, respectively (unadjusted odds ratio [OR], 4.26 [95% CI, 2.05-8.85]; OR, 12.77 [95% CI, 6.53-24.96]). Menopause and perineal laceration increased the odds of VL by 4 and 6 times (unadjusted OR, 4.65 [95% CI, 2.73-7.93]; OR, 6.13 [95% CI, 3.58-10.49]). In multivariate analysis, menopause, primiparity, multiparity, and POP remained associated with VL. CLINICAL IMPLICATIONS: Parity, as an obstetric factor, and menopause and staging of POP, as clinical factors, were associated with VL. STRENGTHS AND LIMITATIONS: The investigation of associated factors for VL will contribute to the understanding of its pathophysiology. The study design makes it impossible to carry out causal inference. CONCLUSION: Menopause, primiparity, multiparity, and POP were highly associated with VL complaints in multivariate analysis.
Assuntos
Paridade , Qualidade de Vida , Disfunções Sexuais Fisiológicas , Vagina , Humanos , Feminino , Estudos Transversais , Disfunções Sexuais Fisiológicas/epidemiologia , Disfunções Sexuais Fisiológicas/etiologia , Pessoa de Meia-Idade , Adulto , Prolapso de Órgão Pélvico/epidemiologia , Inquéritos e Questionários , Menopausa/fisiologia , Parto Obstétrico/estatística & dados numéricos , Parto Obstétrico/efeitos adversos , Fatores de Risco , GravidezRESUMO
BACKGROUND: Despite several treatments that have been used for women reporting vaginal laxity (VL), to our knowledge no systematic review is available on the topic so far. AIM: In this study, we sought to summarize the best available evidence about the efficacy and safety of interventions for treating VL, whether conservative or surgical. METHODS: A comprehensive search strategy was performed in Medline, Embase, Scopus, Web of Science, and Cochrane Library for reports of clinical trials published from database inception to September 2022. Studies selected for inclusion were in the English language and were performed to investigate any type of treatment for VL, with or without a comparator, whether nonrandomized studies or randomized controlled trials (RCTs). Case reports and studies without a clear definition of VL were excluded. OUTCOMES: The outcomes were interventions (laser, radiofrequency, surgery, and topical treatment), adverse effects, sexual function, pelvic floor muscle (PFM) strength, and improvement of VL by the VL questionnaire (VLQ). RESULTS: From 816 records, 38 studies remained in the final analysis. Laser and radiofrequency (RF) were the energy-based treatment devices most frequently studied. Pooled data from eight observational studies have shown improved sexual function assessed by a Female Sexual Function Index score mean difference (MD) of 6.51 (95% CI, 5.61-7.42; i2 = 85%, P < .01) before and after intervention, whether by RF (MD, 6.00; 95% CI, 4.26-7.73; i2 = 80%; P < .001) or laser (MD, 6.83; 95% CI, 5.01-8.65; i2 = 92%; P < .01). However, this finding was not shown when only 3 RCTs were included, even when separated by type of intervention (RF or laser). When RF treatment was compared to sham controls, VLQ scores did not improve (MD, 1.01; 95% CI, -0.38 to 2.40; i2 = 94%; P < .001). Patient PFM strength improved after interventions were performed (MD, 4.22; 95% CI, 1.02-7.42; i2 = 77%; P < .001). The ROBINS-I (Risk Of Bias In Nonrandomized Studies of Interventions) tool classified all non-RCTs at serious risk of bias, except for 1 study, and the risk of bias-1 analysis found a low and unclear risk of bias for all RCTs. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) certainty of the evidence was moderate for sexual function and the VLQ questionnaire and low for PFM strength. CLINICAL IMPLICATIONS: Sexual function in women with VL who underwent RF and laser treatment improved in observational studies but not in RCTs. Improvement in PFM strength was observed in women with VL after the intervention. STRENGTHS AND LIMITATIONS: Crucial issues were raised for the understanding of VL, such as lack of standardization of the definition and for the development of future prospective studies. A limitation of the study was that the heterogeneity of the interventions and different follow-up periods did not make it possible to pool all available data. CONCLUSIONS: Vaginal tightening did not improve sensation in women with VL after intervention, whereas RF and laser improved sexual function in women with VL according to data from observational studies, but not from RCTs. PFM strength was improved after intervention in women with VL.
Assuntos
Vagina , Humanos , Feminino , Vagina/cirurgia , Terapia a Laser/métodos , Diafragma da Pelve/fisiopatologia , Terapia por Radiofrequência/métodos , Disfunções Sexuais Fisiológicas/terapiaRESUMO
OBJECTIVES: To describe the attitudes and perceptions of postmenopausal women from the United Kingdom regarding menopause, vulvo-vaginal atrophy and its therapeutic management. STUDY DESIGN: Post hoc analysis of the United Kingdom population from the REVIVE-EU Study. MAIN OUTCOME MEASURES: The survey contained questions about women's knowledge of menopause and vulvo-vaginal atrophy symptoms, impact on their life and sexual activities, communication with healthcare professionals and treatments. RESULTS: The most frequent symptom of menopause was hot flushes (75%). Vulvo-vaginal atrophy symptoms had a significant impact on participants' ability to enjoy sexual intercourse (66%), spontaneity (62%) and ability to be intimate (61%); however, only 68% of women had been to their healthcare professional for advice. Half of the sample expected that doctors would initiate a discussion of menopausal symptoms and sexual health, but was in fact rare (5%). Only 27% were under current treatment without a clear therapy pattern, of which 43% used vaginal over-the-counter treatments, 28% prescription (Rx), and 13% both. Efficacy was the main limitation for over-the-counter treatments, while for Rx products were side effects and safety. Women highlighted the restoring of the natural condition of the vagina as the main goal for a treatment (35%). Many United Kingdom women did not feel the need to see any healthcare professional for their gynaecological symptoms. Overall satisfaction with treatment was only 44%. CONCLUSIONS: Vulvo-vaginal atrophy remains underdiagnosed and undertreated in United Kingdom. There is a lack of coherent discussion about vulvo-vaginal atrophy symptoms with clinicians. Many United Kingdom healthcare professionals could improve proactive communication with patients about vulvo-vaginal atrophy.
Assuntos
Conhecimentos, Atitudes e Prática em Saúde , Pós-Menopausa , Vagina/patologia , Doenças Vaginais , Vulva/patologia , Doenças da Vulva , Idoso , Atrofia , Feminino , Inquéritos Epidemiológicos , Humanos , Pessoa de Meia-Idade , Pós-Menopausa/fisiologia , Pós-Menopausa/psicologia , Qualidade de Vida , Comportamento Sexual , Reino Unido , Doenças Vaginais/diagnóstico , Doenças Vaginais/patologia , Doenças Vaginais/psicologia , Doenças Vaginais/terapia , Doenças da Vulva/diagnóstico , Doenças da Vulva/patologia , Doenças da Vulva/psicologia , Doenças da Vulva/terapiaRESUMO
Vaginal or vulvovaginal atrophy is a widespread but poorly recognized condition of peri- and post-menopausal women. It causes urogenital symptoms of dryness, reduced lubrication, itching, burning, irritable bladder symptoms and painful intercourse. This impacts quality of life and sexual health, but increases with time rather than reduces, as with most other menopausal symptoms. With early identification, treatments can improve these symptoms and reverse the physical changes. However, when embedded, bladder and sexual changes have occurred and these may be more difficult to remedy. Therefore, it is important to educate both healthcare professionals and women about these symptoms and advise on the range of interventions available.
Assuntos
Androgênios/uso terapêutico , Vaginite Atrófica/tratamento farmacológico , Terapia de Reposição de Estrogênios/métodos , Lubrificantes/uso terapêutico , Ocitócicos/uso terapêutico , Pós-Menopausa , Moduladores Seletivos de Receptor Estrogênico/uso terapêutico , Doenças da Vulva/tratamento farmacológico , Administração Cutânea , Administração Intravaginal , Administração Oral , Atrofia/tratamento farmacológico , Desidroepiandrosterona/uso terapêutico , Feminino , Humanos , Ácido Hialurônico/uso terapêutico , Ocitocina/uso terapêutico , Testosterona/uso terapêutico , Doenças da Vulva/patologiaRESUMO
OBJECTIVE: To understand the physical and emotional impact of postmenopausal vaginal discomfort on relationships between women and their male partners. STUDY DESIGN: In a quantitative, Internet-based survey, 8200 individuals from the UK, Denmark, Sweden, Norway, Finland, France, Italy, US and Canada (postmenopausal, married/cohabiting women, aged 55-65 years, who had experienced vaginal discomfort, and male partners of such women) completed a structured questionnaire. MAIN OUTCOME MEASURES: Results for respondents from the UK (500 men, 500 women), expressed as percentages of women/men describing particular answers, are reported. RESULTS: Avoiding physical intimacy because of vaginal discomfort was reported by 69% of women and 76% of male partners, mainly due to concern about sex being painful (women 63%; men 61%); 18% of women considered vaginal discomfort had created emotional distance between them and their partners. Local estrogen treatment was used by 21% of women, among whom 58% subsequently reported less painful sex. Following such treatment, 33% of women and 30% of male partners reported an improved sex life, while 33% of women and 34% of male partners described becoming emotionally closer. Although 73% of women did not consider enough information about vaginal discomfort to be available, 60% would consult a physician to obtain this. CONCLUSIONS: Although vaginal discomfort has a substantial impact on postmenopausal women and their partners, improvements in sexual and emotional relationships can follow use of local estrogen therapy. Not all women may be aware of therapeutic options; healthcare providers can improve outcomes by more openly communicating and initiating discussion with patients.
Assuntos
Dor/psicologia , Pós-Menopausa/psicologia , Parceiros Sexuais/psicologia , Vagina/patologia , Doenças Vaginais/psicologia , Idoso , Atrofia , Terapia de Reposição de Estrogênios , Feminino , Inquéritos Epidemiológicos , Humanos , Masculino , Pessoa de Meia-Idade , Dor/tratamento farmacológico , Dor/epidemiologia , Prevalência , Comportamento Sexual/psicologia , Inquéritos e Questionários , Resultado do Tratamento , Reino Unido/epidemiologia , Doenças Vaginais/tratamento farmacológico , Doenças Vaginais/epidemiologiaRESUMO
INTRODUCTION: This paper provides a detailed discussion of the psychometric analysis and scoring of a revised measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). METHODS: Standard tools for evaluating item distributions, relationships, and psychometric properties were used to identify sub-scales and determine how the sub-scales should be scored. The evaluation of items included a nonresponse analysis, the nature of missingness, and imputation methods. The minimum number of items required to be answered and three different scoring methods were evaluated: simple summation, mean calculation, and transformed summation. RESULTS: Item nonresponse levels are low in women who are sexually active and the psychometric properties of the scales are robust. Moderate levels of item nonresponse are present for women who are not sexually active, which presents some concerns relative to the robustness of the scales. Single imputation for missing items is not advisable and multiple imputation methods, while plausible, are not recommended owing to the complexity of their application in clinical research. The sub-scales can be scored using either mean calculation or transformed summation. Calculation of a summary score is not recommended. CONCLUSION: The PISQ-IR demonstrates strong psychometric properties in women who are sexually active and acceptable properties in those who are not sexually active. To score the PISQ-IR sub-scales, half of the items must be answered, imputation is not recommended, and either mean calculation or transformed sum methods are recommended. A summary score should not be calculated.
Assuntos
Distúrbios do Assoalho Pélvico/complicações , Prolapso de Órgão Pélvico/complicações , Disfunções Sexuais Fisiológicas/diagnóstico , Inquéritos e Questionários , Feminino , Humanos , Psicometria , Disfunções Sexuais Fisiológicas/etiologiaRESUMO
Heterotopic pregnancy is a well-established complication of assisted reproductive technology. We report a case of intrauterine pregnancy combined with abdominal pregnancy diagnosed at 12 weeks in a 37-year-old nulliparous woman. Following surgical resection of the ectopic, implantation of hemorrhagic ectopic trophoblastic tissue onto bowel serosa, mesentery and omentum persisted. Due to the high risk of additional bleeding, systemic methotrexate was administered to the patient. The intrauterine pregnancy progressed well and a live infant was born at 27(+3) weeks. In such difficult cases, systemic methotrexate appears to have therapeutically helpful effects at low dosing regimens without immediate fetal toxicity.
Assuntos
Abortivos não Esteroides/administração & dosagem , Metotrexato/administração & dosagem , Gravidez Abdominal/cirurgia , Gravidez , Técnicas de Reprodução Assistida/efeitos adversos , Trofoblastos/efeitos dos fármacos , Abortivos não Esteroides/efeitos adversos , Adulto , Feminino , Humanos , Metotrexato/efeitos adversos , Resultado da Gravidez , Gravidez Abdominal/diagnóstico , Gravidez Abdominal/etiologiaRESUMO
Sexual function in women has often been measured by clinicians using parameters which appear easier to assess (frequency and pain). Therefore, the range of normality is often broad and of limited value when investigating population groups. The most important features to explore are satisfaction and/or distress with sexual activity. Although female sexual activity decreases with age, dissatisfaction also declines, and rates of female sexual dysfunction may not change significantly. There are cultural differences in sexual behaviour across the world, but overall a satisfying sexual life is important for women's quality of life.
Assuntos
Comportamento Sexual , Saúde da Mulher , Envelhecimento/fisiologia , Atitude , Feminino , HumanosRESUMO
OBJECTIVE: To evaluate the effect on climacteric symptoms and quality of life, and the safety of four doses of progestelle progesterone cream administered for 24 weeks to postmenopausal women complaining of moderate to severe menopausal symptoms. Design Single-centre, double-blind, randomized, placebo-controlled study. Population Two hundred and twenty-three healthy postmenopausal women, aged between 40 and 60 years and complaining of severe menopausal symptoms were recruited through newspaper advertisements. METHODS: Women were randomly allocated to progestelle progesterone cream 60, 40, 20, 5 mg or placebo, to be applied daily for six months. Main outcome measures The primary efficacy variable was the psychological, somatic and vasomotor components of the Greene Climacteric Scale after six months. Secondary endpoints were incidence of hot flushes and night sweats, the nine subscales of the Medical Outcome Survey Short Form-36 (SF-36), serum progesterone, endometrial thickness and histology after six months. Adverse events were sought and recorded and followed up to resolution. RESULTS: There were no statistically significant differences between any of the treatment groups and placebo for any of the components of the Greene Score. A statistically significant difference between the 20 mg group and placebo was found for the physical functioning (95% confidence interval [CI] 1.7-12.3; P=0.01) and social functioning (95% CI 1.9-16.7; P=0.01) scales of SF-36 after six months. No other statistically significant differences were found between any treatment group and placebo for any of the other secondary efficacy variables. There appeared to be a higher incidence of headache in the groups treated with progesterone cream. CONCLUSIONS: Progesterone cream was no more effective than placebo for relief of menopausal symptoms.